NCT03961165View on ClinicalTrials.gov

BUSCLAB - Buscopan to Prevent Slow Progress in Labor

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

May 25, 2019

Primary Completion Date

August 29, 2021

Study Completion Date

June 16, 2022

Conditions
Labor (Obstetrics)--ComplicationsLabor; Prolonged, First Stage
Interventions
DRUG

Butylscopolamine Bromide 20 MG/ML

1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.

DRUG

Sodium Chloride 9mg/mL

1 mL Sodium Chloride 9 mg/mL i.v. Single dose.

Trial Locations (1)

0424

Oslo University Hospital Rikshospitalet, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT03961165 - BUSCLAB - Buscopan to Prevent Slow Progress in Labor | Biotech Hunter | Biotech Hunter